pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,162 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT921Endpoints710BioPharma Dive271onclive165BioSpace159Fierce Biotech149globenewswire health73raps55
therapy area
allOncology5419Rare Disease1137Cardiology988Hematology886Immunology833Pulmonology704Psychiatry & CNS
  • Danske Bank corrects placement of English PDF in transaction disclosure
    A correction notice was issued for Danske Bank A/S concerning the location of an English PDF file in its public disclosure. The original announcement had both the Danish and English PDFs attached…
    globenewswire health · 6d agoRegulatoryNeutral↗ source
  • Danske Bank corrects webpage to place English PDF in English section
    A correction has been issued for a Danske Bank notification concerning the placement of PDF documents on its website. The original posting attached both the Danish and English versions of the PDF…
    globenewswire health · 6d agoNeutral↗ source
← prev
page 6 of 47
next →
fda recalls35
fda press24
fda medwatch23
643
Vaccines612
Endocrinology & Metabolism320
Ophthalmology313
Pain308
Infectious Disease300
  • Danske Bank discloses share sales by APMH Invest under its buyback program
    On August 5, 2026, Danske Bank A/S filed a market‑abuse regulation report detailing changes in share ownership among its reporting persons. The filing notes that APMH Invest A/S, a shareholder, so…
    globenewswire health · 6d agoRegulatoryNeutral↗ source
  • Danske Bank reports manager share transactions linked to ongoing buy-back program
    Danske Bank A/S filed a notification under the EU Market Abuse Regulation, disclosing transactions made by persons with managerial responsibilities. The filing notes that APMH Invest A/S is contin…
    globenewswire health · 6d agoRegulatoryNeutral↗ source
  • Danske Bank reports share sale by APMH Invest under its buyback program
    Danske Bank A/S filed a regulatory disclosure on 5 August 2026 detailing a change in shareholdings linked to its EU‑mandated market‑abuse reporting requirements. APMH Invest A/S sold shares of Dan…
    globenewswire health · 6d agoRegulatoryNeutral↗ source
  • Danske Bank reports ongoing share buy-back sales by APMH Invest under regulatory disclosure
    On 5 August 2026 Danske Bank A/S filed a notification under the EU Market Abuse Regulation describing transactions by persons required to report to the Danish FSA and Nasdaq Copenhagen. The bank d…
    globenewswire health · 6d agoRegulatoryNeutral↗ source
  • Danske Bank corrects website to move English PDF to English page
    Danske Bank issued a correction notice about the placement of its PDF documents on its website. The original posting attached both the Danish and English PDFs under the Danish version of the page.…
    globenewswire health · 6d agoNeutral↗ source
  • Novo Nordisk shares slide 6% after Wegovy pill sales miss despite earnings beat
    Novo Nordisk reported second‑quarter results that beat both revenue and profit forecasts, posting a profit of $5.15 billion. The company’s oral Wegovy obesity pill generated $496 million in sales,…
    BioSpace · 6d agoEarningsNegative↗ source
  • BioNTech trims full-year COVID-19 vaccine sales outlook by up to 20% amid weak demand
    BioNTech announced it is lowering its full-year sales guidance for its COVID-19 vaccine. The company cut the midpoint of its outlook by almost 20%, moving the range to €1.6-1.9 billion from the pr…
    BioSpace · 6d agoEarningsNegative↗ source
  • Otsuka's Voyxact hits key secondary endpoint in Phase 3 IgA nephropathy trial as BioNTech cuts revenue outlook
    Otsuka announced that its experimental kidney drug Voyxact met a key secondary endpoint in the Phase 3 VISIONARY study of patients with IgA nephropathy. The positive result suggests the therapy ha…
    Endpoints · 6d agoPositive readoutNeutral↗ source
  • Pathos AI signs two cancer deals, including $2 bn contract with China's Alphamab and partnership with AstraZeneca
    Pathos AI announced two new collaborations to expand its oncology pipeline, one with AstraZeneca and another with a subsidiary of China's Alphamab Oncology. The deal with Jiangsu Alphamab Biopharm…
    BioSpace · 7d agoDealPositive↗ source
  • Pathos AI signs major ADC partnership with Chinese biotech Alphamab and targets up to $300M Series E raise
    Pathos AI, a technology and drug development company, announced a major antibody‑drug conjugate (ADC) collaboration with Chinese biotech Alphamab. The firm also disclosed a partnership with AstraZ…
    Endpoints · 7d agoDealPositive↗ source
  • Hinge Health to acquire Cylinder Health for $105 million, expanding into digestive care
    Hinge Health, known for virtual physical therapy, announced it will purchase digestive health startup Cylinder Health. The transaction is a cash deal valued at $105 million, marking Hinge's latest…
    Endpoints · 6d agoDealPositive↗ source
  • Pfizer CEO says $7 billion cash ready for bolt‑on acquisitions and dividend will stay intact
    During its second‑quarter earnings call, analysts asked Pfizer if the company would increase M&A spending as rivals rush to buy biotech assets. CEO Albert Bourla replied that Pfizer currently has…
    BioSpace · 6d agoDealPositive↗ source
  • Pfizer CEO says company has already completed its largest deals, no further acquisitions planned
    Pfizer chief Albert Bourla addressed investors from the New York Stock Exchange floor, noting that the company has already executed its biggest transactions and has roughly $6 billion earmarked for…
    Endpoints · 6d agoDealNeutral↗ source
  • Merck’s anti‑TL1A antibody tulisokibart fails Phase 2b in systemic sclerosis lung disease but succeeds in hidradenitis suppurativa
    Merck reported mixed Phase 2b results for its anti‑TL1A monoclonal antibody tulisokibart, acquired in the 2023 Prometheus Biosciences purchase. In patients with systemic sclerosis‑associated inter…
    BioSpace · 6d agoNegative readoutNeutral↗ source
  • Ambient scribing startups draw attention as Abridge secures $300 million funding
    Last summer, a wave of ambient scribing startups captured the health-tech spotlight. These companies employ artificial-intelligence systems that listen to doctor-patient conversations and automati…
    Endpoints · 6d agoDealNeutral↗ source
  • Pfizer adds $2.5 billion to restructuring, targeting $6 billion savings by 2029
    Pfizer announced an additional $2.5 billion in cost reductions as part of its ongoing restructuring program. The new cuts focus on technology and simplification across commercial, R&D and manufact…
    BioSpace · 6d agoNegative↗ source
  • Akido expands AI-driven patient intake and diagnostic tools to 100 clinics
    Akido, a health‑technology startup, announced it will deploy its artificial‑intelligence platform for patient intake and diagnostic assistance in 100 clinics. The AI system captures patient inform…
    Endpoints · 7d agoDealPositive↗ source
  • Bayer plans German launch of new stroke drug despite healthcare spending cuts
    Bayer announced it will move forward with the launch of its new stroke medication in Germany. The decision comes even though Germany has introduced a new healthcare spending bill that reduces reim…
    Endpoints · 7d agoNeutral↗ source
  • Merck's anti-TL1A antibody shows benefit in hidradenitis suppurativa but misses endpoint in rare lung disease trial
    Merck reported mixed results from its anti‑TL1A antibody, a product of its $10.8 billion acquisition of Prometheus Biosciences. In a mid‑stage study for hidradenitis suppurativa, the antibody met…
    Endpoints · 7d agoNeutral↗ source
  • AstraZeneca and Bristol Myers Squibb rumored to be in talks for a major merger
    Over the weekend, reports emerged that AstraZeneca and Bristol Myers Squibb were reportedly discussing a possible merger. Industry observers note that such a combination would create one of the la…
    Endpoints · 7d agoDealNeutral↗ source
  • Merck to test experimental sac-TMT antibody-drug conjugate with Keytruda in lung cancer trial
    Merck announced it will start a clinical trial testing its experimental antibody-drug conjugate sac-TMT together with the immunotherapy Keytruda in patients with lung cancer. The study will assess…
    Endpoints · 6d agoNeutral↗ source
  • As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
    While both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be mo…
    BioSpace · 6d agoDealNeutral↗ source
  • Pfizer adds $2.5 billion to cost-cutting plan, pushing total savings past $10 billion
    Pfizer announced on Tuesday an additional $2.5 billion of cost reductions across the company, extending its multi-year austerity program. The new cuts bring the cumulative savings effort to more t…
    Endpoints · 7d agoNegative↗ source